22.728 articles found

Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain.

Cederfjäll E, Sahin G, Kirik D.

Neurobiol Dis · 2011-10-25

DOI: 10.1016/j.nbd.2011.10.017PMID: 22048069

TREATMENT OF NEURODEGENERATIVE DISEASE

BARBER ELIZABETH K.

· 2011-10-24

Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy.

Sultana Z, Paleologou KE, Al-Mansoori KM, Ardah MT, Ardah MT, Singh N, Usmani S, Jiao H, Martin FL, Bharath MM, Vali S, El-Agnaf OM.

Neuroscience · 2011-10-20

DOI: 10.1016/j.neuroscience.2011.10.018PMID: 22056602

The PIT: SToPP Trial-A Feasibility Randomised Controlled Trial of Home-Based Physiotherapy for People with Parkinson's Disease Using Video-Based Measures to Preserve Assessor Blinding.

Stack E, Roberts H, Ashburn A.

Parkinsons Dis · 2011-10-20

DOI: 10.1155/2012/360231PMID: 22046578

Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.

Chagniel L, Robitaille C, Lebel M, Cyr M.

Neurobiol Dis · 2011-10-19

DOI: 10.1016/j.nbd.2011.10.011PMID: 22037042

The default mode network integrity in patients with Parkinson's disease is levodopa equivalent dose-dependent.

Krajcovicova L, Mikl M, Marecek R, Rektorova I.

J Neural Transm (Vienna) · 2011-10-15

DOI: 10.1007/s00702-011-0723-5PMID: 22002597

COMBINATIONS OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS

HANSEN JOHN BONDO, THOMSEN MICHAEL S.

· 2011-10-13

Deep brain stimulation in the treatment of chorea.

Edwards TC, Zrinzo L, Limousin P, Foltynie T.

Mov Disord · 2011-10-13

DOI: 10.1002/mds.23967PMID: 21997283

Automated gait analysis in bilateral parkinsonian rats and the role of L-DOPA therapy.

Westin JE, Janssen ML, Sager TN, Temel Y.

Behav Brain Res · 2011-10-12

DOI: 10.1016/j.bbr.2011.10.006PMID: 22008381

Combined STN/SNr-DBS for the treatment of refractory gait disturbances in Parkinson's disease: study protocol for a randomized controlled trial.

Weiss D, Wächter T, Meisner C, Fritz M, Gharabaghi A, Plewnia C, Breit S, Krüger R.

Trials · 2011-10-11

DOI: 10.1186/1745-6215-12-222PMID: 21989388

MicroRNAs in neurodegenerative diseases and their therapeutic potential.

Junn E, Mouradian MM.

Pharmacol Ther · 2011-10-08

DOI: 10.1016/j.pharmthera.2011.10.002PMID: 22008259

Therapeutic high-frequency stimulation of the subthalamic nucleus in Parkinson's disease produces global increases in cerebral blood flow.

Sidtis JJ, Tagliati M, Alterman R, Sidtis D, Dhawan V, Eidelberg D.

J Cereb Blood Flow Metab · 2011-10-05

DOI: 10.1038/jcbfm.2011.135PMID: 21971352